MyMD Pharmaceuticals Inc (MYMD)

[knuts4oe]

Here is an interesting article on "long Covid" that focuses on the possible causes. MYMD is currently conducting a Phase 2 study of Covid 19 induced depression being treated with MYMD-1. I have my fingers crossed that MYMD-1 will be shown to knock down the lingering inflammation that may be the cause of "long Covid" symptoms.
https://www.grid.news/story/science/2022/09/07/how-long-covid-studies-could-help-scientists-solve-the-long-unsolved-mystery-of-post-viral-illnesses/

[knuts4oe]

The July 7 Oramed Letter To Shareholders updates the situation with the Oravax Covid 19 vaccine pill.
https://oramed.com/oramed-letter-to-shareholders/

[BioFan1]

We are going to do very well with this one.

[knuts4oe]

Greatly appreciate your reply!

[BioFan1]

Knuts: This appears to be a routine filing associated with the earlier private sale. The form requires a listing of officers and directors. They are not the buyers. But someone likes the company enough to pay $6,000,000 for shares priced at $4.25 in order to get warrants right to buy more at $5.25. That's confidence in the future.

[knuts4oe]

Desperately need help in understanding this morning's Form D filing with the SEC.
https://ih.advfn.com/stock-market/NASDAQ/mymd-pharmaceuticals-MYMD/stock-news/88944045/small-company-offering-and-sale-of-securities-with
Hope it is saying that the 9 officers and directors of MYMD are eventually acquiring 1.4+ million shares of MYMD @ $5.25 a share, but I can't figure it out!

[knuts4oe]

On 7/26/22 MYMD Pharma announced they were advancing the Healthy Lifespan Phase 2 Trial from the 1st cohort (600 mg) to the next cohort (750 mg). As of today we have not had any info from the 2nd active Phase 2 study, Covid 19 induced depression!
It has occurred to me that any success in treating or eliminating said depression would indicate that the same results would likely be true for all forms of "long covid" as all are dependent on chronic inflammation. That result would quickly qualify MYMD-1 for the CTAP (Coronavirus Treatment Acceleration Program) to speed up MYMD-1's availability for use in fighting "long Covid". MYMD's Chief Scientific Officer, Adam Caplin, has been quoted as saying, "The importance of our upcoming Phase 2 trial(Covid 19 induced depression) can't be overstated", and I suspect he was referring to "long Covid" treatment.
Comments welcomed!

[knuts4oe]

The Oramed website reports that the Oravax vaccine pill being trialed in South Africa for safety, tolerability, and effectiveness will be reporting Cohart 1 results in Q 3, '22 and Cohart 2 in Q 4, '22.

[leifsmith]

Patent filing: Improving Cannabis

https://data.epo.org/publication-server/pdf-document?pn=3755318&ki=B1&cc=EP

[knuts4oe]

GOOD NEWS / BAD NEWS
Don't like the dilution, but we need the funds and it's not much compared to the $100,000,000 authorized!
Thanks for posting!

[Huntewr7]

Some one must think that the price is going up.

[BioFan1]

Private Sale at $4.25/share - Proceeds $5,999,999
Somebody with deep pockets just paid $6 million to acquire shares at $4.25, plus warrants at $5.25. https://www.sec.gov/Archives/edgar/data/1321834/000149315222023314/form424b5.htm

[B and B]

Xxl

[B and B]

Dupe

[deast]

Someone sure doesn't like this company.

[BioFan1]

In the meantime, buying the dips is proving to be a great strategy. This little gem has $50+ possibility. There is a reason top scientists at Hopkins are all over this. Three peer-reviewed animal studies in prestigious journals, all with positive results. Potential to treat multiple diseases. No adverse side effects demonstrated in Phase I human trial. If you are reading this, consider yourself to be one of the lucky ones with the opportunity to get in before Phase II results are out later this year.

[BioFan1]

In the meantime, buying the dips is proving to be a great strategy. This little gem has $50+ possibility. There is a reason top scientists at Hopkins are all over this. Three peer-reviewed animal studies in prestigious journals, all with positive results. Potential to treat multiple diseases. No adverse side effects demonstrated in Phase I human trial. If you are reading this, consider yourself to be one of the lucky ones with the opportunity to get in before Phase II results are out later this year.

[Huntewr7]

We need more board activity. There are still millions of people that have never heard of MYMD. There is also a good chance that life can be prolonged. When we reach 100 posts per day the share price will respond in a very positive manner. All just my opinion.

[BioFan1]

Shorts are trying to salvage their position on modest volume. May present a good opportunity to pick up more shares.

[starkd748]

Headed to 6.65

[leifsmith]

Thanks - great find!

[BioFan1]

NEW ANALYST ON BOARD: Analyst Frank Curzio touted MYMD to Charles Payne (Fox Business news) on Monday. This explains the afternoon surge. Look for the August 8th Cryptocurrency video and go to near the end, around 6 minutes.

https://www.foxbusiness.com/shows/making-money-with-charles-payne

Curzio gives two picks, one of which is MYMD. "Same thing as Humera, the number one selling drug in the world." "Under the radar."

It's happening.

[leifsmith]

Patrick Cox, "The Methuselah Effect How the Trend Toward Longevity is Accelerating ... And Soon Will Turn Your World Upside Down"

Cox has been one of the principal reporters of the development of MYMD-1 and its predecessors.

This book is hard to find and I'm not sure Mauldin is still selling it, although this web page says it's available.

https://www.mauldineconomics.com/landing/the-methuselah-effect

[leifsmith]

Mice: MyMD-1 improves health span and prolongs lifespan

MyMD-1 improves health span and prolongs lifespan in old mice: A non-inferiority study to rapamycin

Elena Sabini 1 , Alison O'Mahony 2 , Patrizio Caturegli 1
"1" is Johns Hopkins Hospital, School of Medicine, Department of Pathology, Baltimore, MD.
"2" is Eurofins Discovery, Phenotypic Services, Burlingame, CA and St. Charles, MO.

https://pubmed.ncbi.nlm.nih.gov/35914953/

Abstract

Aging and age-related diseases represent a compelling therapeutic goal for senolytics and drugs targeting inflammatory or metabolic pathways. We compared MyMD-1, a synthetic derivative of the alkaloid myosmine capable of suppressing TNF-a production, to rapamycin, the best characterized drug endowed with anti-aging properties. In vivo, a longitudinal cohort of 54 C57BL/6 mice, 19-month-old at the start, was randomized to receive MyMD-1, high-dose (126 ppm) rapamycin, or low-dose (14 ppm) rapamycin plus metformin. Each treatment arm included 18 mice (10 females and 8 males) and was followed for 16 months or until death. Lifespan was significantly longer in MyMD-1 than rapamycin (P= 0.019 versus high-dose and 0.01 versus low-dose) in a Cox survival model that accounted for sex and serum levels of IL-6, TNF-a, and IL-17A. MyMD-1 also improved several health span characteristics, resulting in milder body weight loss, greater muscle strength, and slower progression to frailty. In vitro, MyMD-1 and rapamycin were compared using a panel of 12 human primary cell systems (BioMAP Diversity PLUS™) where a total of 148 biomarkers are measured. MyMD-1 possessed anti-proliferative, anti-inflammatory, and anti-fibrotic properties. Many were shared with rapamycin, but MyMD-1 was more active in the inhibition of pro-inflammatory and pro-fibrotic biomarkers. Overall, MyMD-1 emerges as a new compound that, even when begun at an advanced age, induces beneficial effects on health and lifespan by modulating inflammation and tissue remodeling.

Keywords: MyMD-1; aging; health span; inflammaging; lifespan; rapamycin.

[leifsmith]

This sounds right to me.

Ray Blanco, of Three Founders, is one of those leading the way to understanding the importance of control of TNF-alpha.

On August 5, Blanco published an article for members of St. Paul Research: "Mighty Mice Point the Way to Longer, Healthier Lifespans". Blanco described the results of a study conducted at Johns Hopkins University School of Medicine (see my next post for a link). The mice receiving MYMD-1 aged far better than those tested with the nearest known anti-aging competitor.

Blanco believes that the economic impact of MYMD-1 could amount to $trillions. This may sound completely outrageous, but makes sense after reading the work of Patrick Cox (Ray Blanco has, I believe).

A Patrick Cox article from 2011
https://dailyreckoning.com/the-holy-grail-of-medicine/
Cox was following the work of Jonnie Williams even then.

[BioFan1]

Friends: don't expect news. All the news is already out there, in the form of multiple, peer reviewed, scientific reports and prestigious Journal articles showing this compound has the potential to revolutionize healthcare. It's just that until now, no one who matters has noticed, because all biotech firms with no revenue are suspect. The suppression of TFN alpha and associated inflammatory processes, especially without horrible side effects (e.g., like those accompanying Humera) is a holy grail of medicine. MYMD is safe (it breezed through Phase 1) and has been shown to significantly lower TFN alpha.

All biotechs are to some degree a speculative bet. But would you rather bet on a compound that treats some obscure disease (or one type of cancer) or one that might treat every inflammatory disease known to man, from arthritis to diabetes. My money (and it's a big chunk of it) is on MYMD.

The action today suggests that some big hitters are figuring this out. It also suggests that all the sellers are gone.

[leifsmith]

Trade hot late in day

Between 12:45 and 2:00 ET close to 1,500,000 shares at increasing prices. Closed up 23% at $5.70.

Why? Maybe we find out tomorrow

[knuts4oe]

Looking like the fires been lit under MYMD!

[knuts4oe]

ANOTHER WONDER DRUG JOINS THE FRAY!
https://www.healtheuropa.com/alzheimers-disease-is-plasticity-sciences-big-breakthrough/115915/

[jeb123]

Hi everyone, company seems positive, new to the board, not many comments?
I understand that we may be early in the game but honestly what do you guys' think is possible here over the next year+

GLTA $$$$ MyMD

[knuts4oe]

Very disappointed at the muted reaction to the mouse study news (currently down .02), though the volume is strong. You know who may be selling into uptrend to prevent what might have been a normal positive upmove.

[leifsmith]

MyMD Pharmaceuticals, Inc. just sent this email:

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Click here to read the full article: https://ir.mymd.com/news-events/press-releases/detail/38/data-showing-mymd-pharmaceuticals-mymd-1-may-extend

If you have any questions, or would like to contact Investor Relations, please reply to this email.

MyMD Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 601, Baltimore, MD 21205 United States of America
https://www.mymd.com

[Huntewr7]

Knuts4oe, I now find myself discovered and proud owner of of March 2023 Option Calls.
Looking for this to at least double in that time frame. It could go much higher with the right information. Go MYMD

[knuts4oe]

The attached current video highlights the importance of inflammation in the development of ALZHEIMERS, but hasn't yet discovered MYMD-1.

https://www.nbcnews.com/health/aging/targeting-brain-inflammation-key-beating-alzheimer-s-disease-n1014121

[leifsmith]

I think you are right.

[B and B]

Spot on Knuts4oe (John’s Hopkins obviously knows how disruptive Mymd can be to the whole medical/biotech industry). This is just the beginning

[knuts4oe]

Have been following this story since June 2009 when an option strategy I was using went awry, and I became an unwilling owner of shares of STSI, Star Scientific, and an eventual fan of Jonnie Williams Sr. through anatabine, Rock Creek Pharma, and now MYMD. After all these years of reading about many different medications, and slogging through countless patent applications, I have finally come to the conclusion that what MyMD Pharmaceuticals is trying to do is the most significant advance in human and mammalian health since the discovery of antibiotics.
And it is so simple! Inflammation is normal, but chronic inflammation can be disruptive and deadly. Modulate inflammation with MYMD-1, and you eliminate hundreds of diseases and other medical problems!

[mrboom]

https://www.ophthalmologytimes.com/view/mymd-pharmaceuticals-bascom-palmer-eye-institute-to-study-mymd-1-in-ophthalmic-conditions

[leifsmith]

I would like to extend thanks to you, as well.

[knuts4oe]

Thanks, leifsmith, for the very substantial contribution to the otherwise minimal discussion on this board.
Seems like it would be fairly easy to structure a partnership with an Abbie Vie ( think Humira), to make it very profitable for Abbie, since they are most at risk from a successful MYMD-1.
Also, the arrangements being forged with The Arthritis Foundation and Bascom Palmer are good examples of cooperation where the partner has much to gain from that relationship. We would like to see more of these relationships where others see MyMD Pharmaceuticals as a valuable partner!

[leifsmith]

Ray Blanco, business writer, just emailed a positive note on MyMD

"MYMD Pharmaceuticals (NASDAQ: MYMD) reported strong progress this weekon its Phase 2 sarcopenia and anti-aging trial!"

Copyrighted, so cannot repost. But nothing readers of this board don't know.

[leifsmith]

Aware of that book, agree with its thesis, have not read it.

IR at MyMD told me one strategy might be to make a deal on MYMD-1 with a big pharma company. Since MYMD-1 poses a substantial threat to the market for biologics (Enbrel, Humira, etc.) the deal should be structured to make it a bad idea for the "partner" to shelve MYMD-1 and hope the world never hears of it again.

One the other hand, if a deal is not made the government servants of big pharma may destroy MyMD Pharmaceuticals.

We remember what happened to Star Scientific.

Trying to improve things in a world of a government entangled markets is a dangerous game.

[knuts4oe]

What do you think!
https://www.psychologytoday.com/us/blog/the-modern-brain/202207/serotonin-doesnt-cause-depression-so-what-does
So if it is not serotonin, maybe it is inflammation. The current phase 2 human study on Covid induced depression should tell us a lot.
GO MYMD-1!

[knuts4oe]

A recent book called "Sickening" by John Abramson describes how healthcare in America is limited to treating symptoms in the most expensive way possible because of the financial dominance of the pharmaceutical industry. While MYMD's first two human studies do not challenge that dominance as there are no drugs treating healthy life extension or long Covid, a human study of MYMD-1 and its impact on rheumatoid arthritis would be of great concern. Add to that, the fact that MYMD-1 appears to treat over 100+ other diseases and medical conditions for which there are no current meds, and we have a situation where "big pharma" would like MyMD Pharmaceuticals to cease existing!!!!!

[B and B]

For those wondering why the stock was down yesterday go to mymd on the nasdaq website and look at the short interest. It doubled from July 1-15 and only growing. The shorts control the direction of the stock until it turns from a retail to institutional investor base. The shorts have hit the stock on every press release over the past year. They are fighting time. Will be fun to watch it play out !!!!

[leifsmith]

Today's movement in MYMD mirrored the weakness you noted in today's PR. Kind of pathetic. They should just keep quiet until there is something of substance to report. And, there will be.

[knuts4oe]

Today's news release looks more like a feeble attempt to give some support to the stock price by getting the company name before the public, rather than being a significant announcement of study progress. There are 4 cohorts at increasing dosages, and this is just a move to the next dosage level, there having been no problems at the initial level.

[leifsmith]

Press Release: Phase 2 Clinical Trial Advances, 26Jul22

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

https://ir.mymd.com/news-events/press-releases/detail/37/mymd-pharmaceuticals-advances-phase-2-multi-center

[knuts4oe]

You said, "This is a straw in the wind, a good one. I'm paying attention."
This got me to pondering the BASCOM PALMER news release with more consideration than usual, and began wondering if maybe it is a model for future ventures where our partner pays the bill. This may be because I had been wondering if The Arthritis Foundation was going to contribute toward the expense of the MYMD-1 / rheumatoid arthritis phase 2 study.
Were we able to "collaborate" with The Arthritis Foundation in a similar manner as BASCO PALMER, and with The Diabetes Foundation, the groups seeking a cure for inflammatory diseases and inflammatory cancers, we would be going a long ways toward solving the finances problem!

[leifsmith]

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute

https://www.businesswire.com/news/home/20220712005361/en/
[a different link to same info was posted earlier by knuts4oe]

This is a straw in the wind, a good one. I'm paying attention.

MyMD, a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that it has entered into a material transfer agreement (MTA) with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1® as a potential treatment for traumatic optic neuropathy (TON). The project is fully funded by Bascom Palmer Eye Institute.

bascom-palmer-eye-institute